Viking Therapeutics Misses Q1 Estimates as Loss Widens on Higher R&D
VKTX sits 38% above its 52-week low of $22.959.
Summary
Viking Therapeutics reported a significantly wider net loss for Q1, missing analyst expectations for both EPS and net income. The company posted an EPS of -$1.37 against a consensus of -$1.01, and a net loss of -$158.33 million compared to an -$113.79 million estimate. This increased loss was primarily driven by higher research and development expenses as the company advanced its Phase 3 VK2735 obesity trials, with both VANQUISH-1 and VANQUISH-2 fully enrolled. While the recent 10-K indicated an expected increase in R&D due to clinical development, the specific Q1 financial underperformance and miss against estimates are new and material. Traders will monitor the stock's reaction to these results and look for updates on the expected initiation of the Phase 3 oral VK2735 obesity trial in Q4 2026 and maintenance dosing study data in Q3 2026.
At the time of this announcement, VKTX was trading at $31.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $22.96 to $43.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.